220 related articles for article (PubMed ID: 21079419)
1. Effect of VEGF and VEGF Trap on vascular endothelial cell signaling in tumors.
Lassoued W; Murphy D; Tsai J; Oueslati R; Thurston G; Lee WM
Cancer Biol Ther; 2010 Dec; 10(12):1326-33. PubMed ID: 21079419
[TBL] [Abstract][Full Text] [Related]
2. Ellagic acid inhibits VEGF/VEGFR2, PI3K/Akt and MAPK signaling cascades in the hamster cheek pouch carcinogenesis model.
Kowshik J; Giri H; Kishore TK; Kesavan R; Vankudavath RN; Reddy GB; Dixit M; Nagini S
Anticancer Agents Med Chem; 2014; 14(9):1249-60. PubMed ID: 25060902
[TBL] [Abstract][Full Text] [Related]
3. Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects.
Li D; Xie K; Zhang L; Yao X; Li H; Xu Q; Wang X; Jiang J; Fang J
Cancer Lett; 2016 Jul; 377(2):164-73. PubMed ID: 27130666
[TBL] [Abstract][Full Text] [Related]
4. Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3'-kinase activity.
Bagli E; Stefaniotou M; Morbidelli L; Ziche M; Psillas K; Murphy C; Fotsis T
Cancer Res; 2004 Nov; 64(21):7936-46. PubMed ID: 15520200
[TBL] [Abstract][Full Text] [Related]
5. Activated STAT3 is a mediator and biomarker of VEGF endothelial activation.
Chen SH; Murphy DA; Lassoued W; Thurston G; Feldman MD; Lee WM
Cancer Biol Ther; 2008 Dec; 7(12):1994-2003. PubMed ID: 18981713
[TBL] [Abstract][Full Text] [Related]
6. L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways.
Gao F; Vasquez SX; Su F; Roberts S; Shah N; Grijalva V; Imaizumi S; Chattopadhyay A; Ganapathy E; Meriwether D; Johnston B; Anantharamaiah GM; Navab M; Fogelman AM; Reddy ST; Farias-Eisner R
Integr Biol (Camb); 2011 Apr; 3(4):479-89. PubMed ID: 21283904
[TBL] [Abstract][Full Text] [Related]
7. Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction.
Masuda M; Suzui M; Lim JT; Deguchi A; Soh JW; Weinstein IB
J Exp Ther Oncol; 2002; 2(6):350-9. PubMed ID: 12440226
[TBL] [Abstract][Full Text] [Related]
8. Early Actions of Anti-Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Drugs on Angiogenic Blood Vessels.
Sitohy B; Chang S; Sciuto TE; Masse E; Shen M; Kang PM; Jaminet SC; Benjamin LE; Bhatt RS; Dvorak AM; Nagy JA; Dvorak HF
Am J Pathol; 2017 Oct; 187(10):2337-2347. PubMed ID: 28736316
[TBL] [Abstract][Full Text] [Related]
9. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis.
von Marschall Z; Scholz A; Cramer T; Schäfer G; Schirner M; Oberg K; Wiedenmann B; Höcker M; Rosewicz S
J Natl Cancer Inst; 2003 Mar; 95(6):437-48. PubMed ID: 12644537
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
11. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
Ding C; Li L; Yang T; Fan X; Wu G
BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
[TBL] [Abstract][Full Text] [Related]
12. ARTEMIN promotes de novo angiogenesis in ER negative mammary carcinoma through activation of TWIST1-VEGF-A signalling.
Banerjee A; Wu ZS; Qian PX; Kang J; Liu DX; Zhu T; Lobie PE
PLoS One; 2012; 7(11):e50098. PubMed ID: 23185544
[TBL] [Abstract][Full Text] [Related]
13. Tumor Suppression Efficacy of Heat Shock Protein 90 Inhibitor 17AAG in a Liposarcoma Mouse Model.
Nam S; Kim H; Hong D; Park JB; Kim SJ
Anticancer Res; 2017 Nov; 37(11):6291-6302. PubMed ID: 29061812
[TBL] [Abstract][Full Text] [Related]
14. Activation of the VEGF-A/ERK/PLA2 Axis Mediates Early Retinal Endothelial Cell Damage Induced by High Glucose: New Insight from an In Vitro Model of Diabetic Retinopathy.
Giurdanella G; Lupo G; Gennuso F; Conti F; Furno DL; Mannino G; Anfuso CD; Drago F; Salomone S; Bucolo C
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33065984
[TBL] [Abstract][Full Text] [Related]
15. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways.
Xu Q; Briggs J; Park S; Niu G; Kortylewski M; Zhang S; Gritsko T; Turkson J; Kay H; Semenza GL; Cheng JQ; Jove R; Yu H
Oncogene; 2005 Aug; 24(36):5552-60. PubMed ID: 16007214
[TBL] [Abstract][Full Text] [Related]
16. Tie2 in tumor endothelial signaling and survival: implications for antiangiogenic therapy.
Tsai JH; Lee WM
Mol Cancer Res; 2009 Mar; 7(3):300-10. PubMed ID: 19276184
[TBL] [Abstract][Full Text] [Related]
17. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2.
Zhang Z; Neiva KG; Lingen MW; Ellis LM; Nör JE
Cell Death Differ; 2010 Mar; 17(3):499-512. PubMed ID: 19834490
[TBL] [Abstract][Full Text] [Related]
18. AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells.
Frost P; Shi Y; Hoang B; Lichtenstein A
Oncogene; 2007 Apr; 26(16):2255-62. PubMed ID: 17016437
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic Potential of Microbial Metabolite Elaiophylin for Targeting Tumor Angiogenesis.
Lim HN; Jang JP; Han JM; Jang JH; Ahn JS; Jung HJ
Molecules; 2018 Mar; 23(3):. PubMed ID: 29498688
[TBL] [Abstract][Full Text] [Related]
20. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
